Hoke Charles H, Hawksworth Anthony, Snyder Clifford E
U.S. Army Medical Research and Materiel Command Adenovirus Vaccine Integrated Product Team, Fort Detrick, Frederick, MD, USA.
MSMR. 2012 Mar;19(3):2-4.
After a 12-year hiatus, military recruit training centers resumed administration of adenovirus type 4 and type 7 vaccine, live, oral (adenovirus vaccine) to trainees beginning in October of 2011. Subsequently, rates of febrile respiratory illnesses (FRI) and adenovirus isolations markedly declined. These findings are consistent with those of a placebo-controlled efficacy trial conducted prior to the vaccine's licensure by the U.S. Food and Drug Administration. Continued surveillance will clarify the longer term impact of vaccine use.
在中断12年后，军事新兵训练中心于2011年10月开始重新向新兵接种4型和7型腺病毒活口服疫苗（腺病毒疫苗）。随后，发热性呼吸道疾病（FRI）的发病率和腺病毒分离率显著下降。这些发现与美国食品药品监督管理局批准该疫苗之前进行的一项安慰剂对照疗效试验的结果一致。持续监测将阐明疫苗使用的长期影响。
